<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710758</url>
  </required_header>
  <id_info>
    <org_study_id>ZSGC-006</org_study_id>
    <nct_id>NCT04710758</nct_id>
  </id_info>
  <brief_title>Multicenter Study on Laparoscopic Total Gastrectomy for Advanced Gastric Cancer</brief_title>
  <acronym>CLASS-07</acronym>
  <official_title>Prospective Randomized Controlled Multicenter Clinical Trial For Comparison Of Long-term Outcomes Between Laparoscopic And Open Total Gastrectomy In Patients With Locally Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CLASS-07 trial is a prospective, multicenter, randomized controlled trial for comparison of&#xD;
      long-term outcomes between laparoscopic total gastrectomy (LTG) and open total gastrectomy&#xD;
      (OTG) in patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0). The&#xD;
      primary purpose of this study is to evaluate the overall survival and determine the efficacy&#xD;
      of LTG compared with OTG for locally advanced gastric cancer. The second purpose is to&#xD;
      evaluate the 3-year overall survival rate, 3-year disease free survival rate, morbidity and&#xD;
      mortality rates, 3-year recurrence pattern and postoperative recovery course of the patients&#xD;
      enrolled in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer is a significant global health problem, especially in East Asia. With an&#xD;
      increase in the incidences of proximal gastric cancer over the last decades, the value of&#xD;
      total gastrectomy is more emphasized. Laparoscopic total gastrectomy (LTG) has become an&#xD;
      attracting option for surgeons due to its well-known advantages. However, more evidence is&#xD;
      needed to support the safety and efficacy of LTG in locally advanced gastric cancer.&#xD;
&#xD;
      Recently，a multicenter, open-label, noninferiority, randomized clinical trial (CLASS-02)&#xD;
      launched by Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group compared the&#xD;
      safety of LTG for clinical stage I gastric cancer with open total gastrectomy (OTG). The&#xD;
      overall morbidity and mortality rates were 19.1% in the LTG group and 20.2% in the OTG group,&#xD;
      which was not significantly different (rate difference, -1.1%). This study demonstrated that&#xD;
      LTG can be safely performed by experienced surgeons for clinical stage I gastric cancer.&#xD;
      However, there hasn't been any prospective randomized clinical trial study evaluating the&#xD;
      safety and efficacy of LTG in advanced gastric cancer.&#xD;
&#xD;
      This CLASS-07 trial is a prospective, multicenter, randomized controlled trial for comparison&#xD;
      of long-term outcomes between LTG and OTG in patients with locally advanced gastric cancer&#xD;
      (clinical stage T2-4aN0-3M0). The primary purpose of this study is to evaluate the overall&#xD;
      survival and determine the efficacy of LTG compared with OTG for locally advanced gastric&#xD;
      cancer. The second purpose is to evaluate the 3-year overall survival rate, 3-year disease&#xD;
      free survival rate, morbidity and mortality rates, 3-year recurrence pattern and&#xD;
      postoperative recovery course of the patients enrolled in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival (OS) was defined as the time from randomization to death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival rate</measure>
    <time_frame>3 years</time_frame>
    <description># of patients who are still alive at 3 years out of all study patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year disease free survival rate</measure>
    <time_frame>3 years</time_frame>
    <description># of patients who are free of gastric cancer at 3 years out of all study patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early morbidity rate</measure>
    <time_frame>30 days</time_frame>
    <description>The early morbidity are defined as the event observed within 30 days following surgery, including intraoperative and postoperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early mortality rate</measure>
    <time_frame>30 days</time_frame>
    <description>The early mortality are defined as the event observed within 30 days following surgery, including intraoperative and postoperative death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year recurrence pattern</measure>
    <time_frame>3 years</time_frame>
    <description>Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative recovery course</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first ambulation, flatus, liquid diet, and soft diet are used to assess the postoperative recovery course, which is a composite outcome measure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1316</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>Laparoscopic total gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The surgeon will perform LTG with D2 lymphadenectomy for patients enrolled in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open total gastrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The surgeon will perform OTG with D2 lymphadenectomy for patients enrolled in this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic total gastrectomy</intervention_name>
    <description>LTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)</description>
    <arm_group_label>Laparoscopic total gastrectomy</arm_group_label>
    <other_name>Experimental group (LTG)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open total gastrectomy</intervention_name>
    <description>OTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)</description>
    <arm_group_label>Open total gastrectomy</arm_group_label>
    <other_name>Control group (OTG)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-75 years&#xD;
&#xD;
          2. Tumor located in the middle or upper third of the stomach, and curative resection is&#xD;
             expected to be achievable by total gastrectomy with D2 lymphadenectomy (also apply to&#xD;
             multiple primary cancers);&#xD;
&#xD;
          3. Primary lesion is pathologically diagnosed as gastric adenocarcinoma, such as&#xD;
             papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, poorly&#xD;
             cohesive carcinoma (including signet ring cell carcinoma and other variants), and&#xD;
             mixed adenocarcinoma;&#xD;
&#xD;
          4. Clinical stage T2-4aN0-3M0 (According to AJCC-8th TNM staging system);&#xD;
&#xD;
          5. Expected survival &gt; 6 months&#xD;
&#xD;
          6. No invasion to Z-line;&#xD;
&#xD;
          7. BMI (Body Mass Index) &lt; 30 kg/m2&#xD;
&#xD;
          8. No history of upper abdominal surgery (except for laparoscopic cholecystectomy);&#xD;
&#xD;
          9. No prior treatment of chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc&#xD;
&#xD;
         10. Preoperative performance status (ECOG，Eastern Cooperative Oncology Group) of 0 or 1&#xD;
&#xD;
         11. Preoperative ASA (American Society of Anesthesiologists) scoring: I-III&#xD;
&#xD;
         12. Sufficient organ functions&#xD;
&#xD;
         13. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Preoperative examinations indicate regional fusion of enlarged lymph nodes (max&#xD;
             diameter ≥ 3.0cm) or enlargment of spleen hilus lymph nodes&#xD;
&#xD;
          2. Women during pregnancy or breast-feeding&#xD;
&#xD;
          3. Synchronous or metachronous (within 5 years) malignancies&#xD;
&#xD;
          4. Body temperature ≥ 38℃ before surgery or infectious disease with a systemic therapy&#xD;
             indicated&#xD;
&#xD;
          5. Severe mental disease&#xD;
&#xD;
          6. Severe respiratory disease, FEV1 &lt; 50% of predicted&#xD;
&#xD;
          7. Severe hepatic and renal dysfunction&#xD;
&#xD;
          8. Unstable angina pectoris or history of myocardial infarction within 6 months&#xD;
&#xD;
          9. History of cerebral infarction or cerebral hemorrhage within 6 months&#xD;
&#xD;
         10. Continuous systemic steroid therapy within 1 month (except for topical use)&#xD;
&#xD;
         11. Gastric cancer complications (bleeding, perforation, obstruction) that requiring&#xD;
             emergency surgery&#xD;
&#xD;
         12. Patients are participating or have participated in another clinical trial (within 6&#xD;
             months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yihong Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yihong Sun, MD</last_name>
    <phone>86-21-64041990</phone>
    <email>sun.yihong@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>ZhongShan hospital FuDan university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yihong Sun, MD</last_name>
      <phone>86-13701735406</phone>
      <email>sun.yihong@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Yihong Sun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Yang L, Zheng R, Wang N, Yuan Y, Liu S, Li H, Zhang S, Zeng H, Chen W. Incidence and mortality of stomach cancer in China, 2014. Chin J Cancer Res. 2018 Jun;30(3):291-298. doi: 10.21147/j.issn.1000-9604.2018.03.01.</citation>
    <PMID>30046223</PMID>
  </reference>
  <reference>
    <citation>Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M; Japanese Gastric Cancer Association and the Japan Esophageal Society. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 2017 Mar;20(Suppl 1):69-83. doi: 10.1007/s10120-016-0663-8. Epub 2016 Oct 28.</citation>
    <PMID>27796514</PMID>
  </reference>
  <reference>
    <citation>Liu K, Yang K, Zhang W, Chen X, Chen X, Zhang B, Chen Z, Chen J, Zhao Y, Zhou Z, Chen L, Hu J. Changes of Esophagogastric Junctional Adenocarcinoma and Gastroesophageal Reflux Disease Among Surgical Patients During 1988-2012: A Single-institution, High-volume Experience in China. Ann Surg. 2016 Jan;263(1):88-95. doi: 10.1097/SLA.0000000000001148.</citation>
    <PMID>25647058</PMID>
  </reference>
  <reference>
    <citation>Kitano S, Iso Y, Moriyama M, Sugimachi K. Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc. 1994 Apr;4(2):146-8. Erratum in: Surg Laparosc Endosc. 2013 Oct;23(5):480.</citation>
    <PMID>8180768</PMID>
  </reference>
  <reference>
    <citation>Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH, Lee HJ; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). Ann Surg. 2016 Jan;263(1):28-35. doi: 10.1097/SLA.0000000000001346.</citation>
    <PMID>26352529</PMID>
  </reference>
  <reference>
    <citation>Katai H, Mizusawa J, Katayama H, Takagi M, Yoshikawa T, Fukagawa T, Terashima M, Misawa K, Teshima S, Koeda K, Nunobe S, Fukushima N, Yasuda T, Asao Y, Fujiwara Y, Sasako M. Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912. Gastric Cancer. 2017 Jul;20(4):699-708. doi: 10.1007/s10120-016-0646-9. Epub 2016 Oct 7.</citation>
    <PMID>27718137</PMID>
  </reference>
  <reference>
    <citation>Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021 Jan;24(1):1-21. doi: 10.1007/s10120-020-01042-y. Epub 2020 Feb 14.</citation>
    <PMID>32060757</PMID>
  </reference>
  <reference>
    <citation>Lee HJ, Hyung WJ, Yang HK, Han SU, Park YK, An JY, Kim W, Kim HI, Kim HH, Ryu SW, Hur H, Kong SH, Cho GS, Kim JJ, Park DJ, Ryu KW, Kim YW, Kim JW, Lee JH, Kim MC; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT). Ann Surg. 2019 Dec;270(6):983-991. doi: 10.1097/SLA.0000000000003217.</citation>
    <PMID>30829698</PMID>
  </reference>
  <reference>
    <citation>Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J, Xue Y, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Chen P, Liu H, Zheng C, Liu F, Yu J, Li Z, Zhao G, Chen X, Wang K, Li P, Xing J, Li G. Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial. J Clin Oncol. 2016 Apr 20;34(12):1350-7. doi: 10.1200/JCO.2015.63.7215. Epub 2016 Feb 22.</citation>
    <PMID>26903580</PMID>
  </reference>
  <reference>
    <citation>Yu J, Huang C, Sun Y, Su X, Cao H, Hu J, Wang K, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Hu Y, Liu H, Zheng C, Li P, Xie J, Liu F, Li Z, Zhao G, Yang K, Liu C, Li H, Chen P, Ji J, Li G; Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. JAMA. 2019 May 28;321(20):1983-1992. doi: 10.1001/jama.2019.5359.</citation>
    <PMID>31135850</PMID>
  </reference>
  <reference>
    <citation>Kawamura H, Yokota R, Homma S, Kondo Y. Comparison of invasiveness between laparoscopy-assisted total gastrectomy and open total gastrectomy. World J Surg. 2009 Nov;33(11):2389-95. doi: 10.1007/s00268-009-0208-y.</citation>
    <PMID>19760315</PMID>
  </reference>
  <reference>
    <citation>Wang W, Zhang X, Shen C, Zhi X, Wang B, Xu Z. Laparoscopic versus open total gastrectomy for gastric cancer: an updated meta-analysis. PLoS One. 2014 Feb 18;9(2):e88753. doi: 10.1371/journal.pone.0088753. eCollection 2014.</citation>
    <PMID>24558421</PMID>
  </reference>
  <reference>
    <citation>Hyung WJ, Yang HK, Han SU, Lee YJ, Park JM, Kim JJ, Kwon OK, Kong SH, Kim HI, Lee HJ, Kim W, Ryu SW, Jin SH, Oh SJ, Ryu KW, Kim MC, Ahn HS, Park YK, Kim YH, Hwang SH, Kim JW, Cho GS. A feasibility study of laparoscopic total gastrectomy for clinical stage I gastric cancer: a prospective multi-center phase II clinical trial, KLASS 03. Gastric Cancer. 2019 Jan;22(1):214-222. doi: 10.1007/s10120-018-0864-4. Epub 2018 Aug 20.</citation>
    <PMID>30128720</PMID>
  </reference>
  <reference>
    <citation>Katai H, Mizusawa J, Katayama H, Kunisaki C, Sakuramoto S, Inaki N, Kinoshita T, Iwasaki Y, Misawa K, Takiguchi N, Kaji M, Okitsu H, Yoshikawa T, Terashima M; Stomach Cancer Study Group of Japan Clinical Oncology Group. Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401. Gastric Cancer. 2019 Sep;22(5):999-1008. doi: 10.1007/s10120-019-00929-9. Epub 2019 Feb 20.</citation>
    <PMID>30788750</PMID>
  </reference>
  <reference>
    <citation>He H, Li H, Su X, Li Z, Yu P, Huang H, Huang C, Ye J, Li Y, Suo J, Yu J, Li G, Xu Z, Zhao G, Cao H, Hu J, Du X, Liu F, Sun Y; Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. Study on safety of laparoscopic total gastrectomy for clinical stage I gastric cancer: the protocol of the CLASS02-01 multicenter randomized controlled clinical trial. BMC Cancer. 2018 Oct 3;18(1):944. doi: 10.1186/s12885-018-4846-z.</citation>
    <PMID>30285673</PMID>
  </reference>
  <reference>
    <citation>Liu F, Huang C, Xu Z, Su X, Zhao G, Ye J, Du X, Huang H, Hu J, Li G, Yu P, Li Y, Suo J, Zhao N, Zhang W, Li H, He H, Sun Y; Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1590-1597. doi: 10.1001/jamaoncol.2020.3152.</citation>
    <PMID>32815991</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 2, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Laparoscopic total gastrectomy</keyword>
  <keyword>Open total gastrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

